CardioSecur® – Outshining the Mobile ECG Market
Companies in the space are proudly presenting 1-lead and 6-lead ECG solutions. CardioSecur offers since its inception 10 years ago easy to use, lightweight mobile ECG devices with up to 22-leads for private users and medical professionals.
By: Personal MedSystems
The number of leads determines the level of diagnostic power an ECG has. Each lead represents a visual axis on the heart. The more viewing axes a system has, the more sophisticated and medically relevant is its data. This means, that 1-lead-ECGs (e.g. Apple WatchTM, Alivecor KardiaTM) are only of limited medical value. They can serve as a screening tool that may hint at some forms of arrhythmia. But do not meet the diagnostic requirements of the ESC and the AHA. Their guidelines require a 12-lead ECG even for the diagnosis of arrhythmias. Gadget ECGs cannot detect all forms of arrhythmia and are unable to provide any indication about life-threatening heart attacks.
Still, some ECG device manufacturers (e.g. AlivecorTM Kardia Mobile 6LTM) claim that 6-lead ECGs go "after the Holy Grail [of ECGs]". However, such bold claims do not correspond to diagnostic reality. According to cardiology guidelines, the diagnostic significance of a 6-lead ECG does not exceed that of a 1-lead ECG. In today's medical settings, 6-lead technology has been outdated since the 1940s. For decades 12-lead ECGs with 10 electrodes, have served as the so called "Gold Standard". Medical professionals worldwide make use of this technology. Yet, even the "Gold Standard" ECG has its limitations as it tends to focus on the front side of the human heart. This falls short of guidelines of the ESC and the AHA. They recommend evaluating all sides of the heart including posterior and both lateral sides. This requires multiple repositioning of the 10 electrodes in order to receive a more complete, but asynchronous view of the heart. Due to these restrictions it is hardly ever implemented in practice.
CardioSecur is the first technology outshining the "Gold Standard" by allowing a synchronous 360-degree view of the heart. The system records a fully-ESC compliant ECG in one reading. With only 4 electrodes it serves the highest ease of use in its class. It maximizes doctor's diagnostic power to reveal any type of arrhythmia including atrial fibrillation and life-threatening heart attack on any side of the heart. Other companies are still trying to fulfill the "promise of getting closer to a 12-lead ECG". Meanwhile, CardioSecur is several steps ahead with its ultralight ECG devices with up to 22-leads. CardioSecur provides highly personalized ECG evaluation. Every reading compares the previously stored reference ECG like a "fingerprint of the heart", against the current state of health. Serial ECG-recordings like that are explicitly required by both ESC and AHA. The benefits of such personalized ECG comparisons cannot be overstated. Its sophisticated methodology helps CardioSecur doctors to swiftly conclude all-encompassing diagnosis, initiate targeted therapy and avoid comorbidities due to delays. Gadget ECG devices can only speculate about heart problems and always depend on confirmation by a more powerful ECG to reach conclusive diagnosis. CardioSecur goes far beyond what others deem to be the "Holy Grail" or the "gold standard" and through guideline-compliant ECG technology it has set new milestones in quality and diagnostic efficacy.
Additional information at www.cardiosecur.com
Personal MedSystems GmbH